AstraZeneca PLC AZN-GB:London Stock Exchange

RT Quote | Exchange | GBp
Last | 09/30/22 BST
9,944.00quote price arrow up+11.00 (+0.11%)
52 week range
8,090.32 - 11,540.00
Loading...
  • Open9,966.00
  • Day High10,038.00
  • Day Low9,893.00
  • Prev Close9,933.00
  • 52 Week High11,540.00
  • 52 Week High Date08/25/22
  • 52 Week Low8,090.32
  • 52 Week Low Date12/07/21

Key Stats

  • Market Cap171,010.77M
  • Shares Out1,549.48M
  • 10 Day Average Volume2.71M
  • Dividend221.70
  • Dividend Yield2.23%
  • Beta0.25
  • YTD % Change14.59

KEY STATS

  • Open9,966.00
  • Day High10,038.00
  • Day Low9,893.00
  • Prev Close9,933.00
  • 52 Week High11,540.00
  • 52 Week High Date08/25/22
  • 52 Week Low8,090.32
  • 52 Week Low Date12/07/21
  • Market Cap171,010.77M
  • Shares Out1,549.48M
  • 10 Day Average Volume2.71M
  • Dividend221.70
  • Dividend Yield2.23%
  • Beta0.25
  • YTD % Change14.59

RATIOS/PROFITABILITY

  • EPS (TTM)-69.31
  • P/E (TTM)-143.47
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date08/11/2022
  • Div Amount76.40
  • Split Date-
  • Split Factor-

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development....
Michel Demare
Non-Executive Independent Chairman of the Board - Designate
Leif Johansson
Independent Non-Executive Chairman of the Board
Pascal Soriot
Chief Executive Officer, Executive Director
Aradhana Sarin M.D.
Chief Financial Officer, Executive Director
Ruud Dobber Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Address
1 Francis Crick Avenue
Cambridge
CB2 0AA
United Kingdom